Monsenso has signed an agreement with Awakn Life Sciences, a global biotech company

Monsenso has signed an agreement with Awakn Life Sciences, a global biotech company

Monsenso has signed an agreement with, a global biotech company, to support the company’s medical psychedelic treatments. Awakn Life Sciences is a global biotech company that leads the field of psychedelic medicine for the treatment of addiction. In October 2021 commenced the implementation of the Monsenso Digital Health Solution in Awakn Life Sciences clinical practice as a tool for supporting patients throughout their treatment while capturing real-world patient insights to inform clinical decision-making and personalised treatment.

Mental illness and addiction are some of the biggest public health challenges facing the global community.

Nearly one billion people worldwide suffer from mental illness, for which there are too few effective treatments available beyond coping strategies and treating symptoms. With global spending on mental health estimated to reach $16 trillion by 2030 (as measured by lost economic output)[1], it is critical that effective new treatments are developed to address the current gaps. Psychedelic-assisted therapy has emerged as a potential solution to this treatment vacuum. In the early 20th century, these substances were severely restricted and had a negative connotation. Today, however, a growing body of evidence and urgent unmet patient needs have led clinicians and regulators to consider them as a viable treatment option.

Psychedelic-Assisted Psychotherapy represents a paradigm shift in psychiatric treatment

Psychedelic drugs are substances that alter perception and mood and affect various cognitive processes. When used in conjunction with psychotherapy, they can put patients in a temporary state where they can better process memories, emotions, and past traumas[2], allowing for processing that enables subjects to let go of things that have previously troubled them[3]. For the same reason, psychedelic-assisted psychotherapy has shown effective in treating historically difficult-to-treat illnesses[4] and is today considered a promising game-changer in psychiatric treatment[5,6,7].

While psychedelics have spurred great interest in the life science industry, only a few psychedelic companies are currently treating patients in the clinical setting. Awakn Life Sciences launched the UK’s first psychedelic-assisted clinic in Bristol, followed by London and Manchester, offering evidence-based psychedelic therapies for addiction and other mental health indications, and has also opened a clinic in Oslo, Norway with plans to scale across Europe quickly.

In October 2021, Awakn Life Science commenced implementation of the Monsenso Digital Health Solution in its clinical practice to support patients throughout their treatment journey and to capture real-world data to inform clinicians’ decision making for personalised patient support and management.

“We are excited to work with Awakn Life Science to support new treatment options for people who have experienced insufficient treatment results. We look forward to partnering with Awakn Life Sciences and be part of their growth journey” says CEO of Monsenso, Thomas Lethenborg.

Awakn’s CEO, Anthony Tennyson added “There’s such a critical need to provide solutions and hope to people suffering from mental illnesses and addiction. We’re excited to partner with Monsenso to better engage with clients throughout their treatment, gain insights to help inform clinical decisions and improve health outcomes, and generate insights that inform our research and treatment development programs”.

About Awakn Life Science Awakn Life Sciences is a publicly-traded (NEO: AWKN) (OTCQB: AWKNF) biotechnology company with clinical operations; researching, developing, and delivering psychedelic medicine to better treat Addiction. Awakn’s team consists of worldleading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies and enabling technologies to treat Addiction.

About Monsenso Monsenso is an innovative technology company offering a digital health solution for mental health and behavioral disorders. Our mission is to help provide better mental health to more people at lower costs. Our solution helps optimise the treatment of mental disorders and gives a detailed overview of an individual’s mental health through the collection of outcome, adherence and behavioural data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. Based on continuous research and development, our team is committed to developing solutions that fit seamlessly into the lives of individuals, increase their quality of life and improve the efficacy of mental health treatment. To learn more visit www.monsenso.com

For additional information contact:
Bettina van Wylich-Muxoll
Chief Marketing Officer
marketing@monsenso.com
Monsenso

Sources:

[1] https://www.weforum.org/agenda/2020/10/mental-health-day-covid19-coronavirus-global/

[2] https://www.health.harvard.edu/blog/back-to-the-future-psychedelic-drugs-in-psychiatry-202106222508

[3] Jennifer Mitchell, neuroscientist and professor in the departments of neurology, psychiatry and behavioral sciences at the University of California San Francisco.

[4] Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development

[5] https://www.health.harvard.edu/blog/back-to-the-future-psychedelic-drugs-in-psychiatry-202106222508

[6] https://www.scientificamerican.com/article/a-renaissance-for-psychedelics-could-fill-a-long-standing-treatment-gap-forpsychiatric-disorders/

[7] Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development

Monsenso is ISO 13485 certified

Monsenso is ISO 13485 certified

Quality Policy and Standards

As a technology leader in mobile health (mHealth) solutions for mental health, Monsenso is ISO 13485 certified. ISO 13485 is the gold standard for medical device companies to ensure the quality, safety and efficacy of products in the medical device field. This certification ensures that the product in question, consistently meets customer requirements and regulatory requirements applicable to medical devices and other related services.

Monsenso adheres to the highest security standards. Beyond, being ISO 13485, Monsenso holds the ISO 27001 certifications, a TGA certification and class 1 CE mark.” says Thomas Lethenborg, CEO at Monsenso.

For additional information contact:
Jennifer Highland
Marketing and Communications Manager
Monsenso
+45 81 71 7713
highland@monsenso.com

Monsenso partners with the Black Dog Institute in Australia

Monsenso partners with the Black Dog Institute in Australia

Copenhagen, Denmark – 30 August 2016.  Monsenso, the Copenhagen-based technology company developing mHealth solutions for mental illnesses, today announced a partnership with The Black Dog Institute in Australia.

Black Dog Institute is a pioneer in the identification, prevention and treatment of mental illness and the promotion of well-being. The Institute will conduct feasibility studies to determine if the Monsenso mHealth solution can be used to collect much needed data for a number of large-scale mental health trials.

“The mission of Monsenso and that of Black Dog are highly aligned. We both aim to enable better mental health care through innovation and science, therefore this is an exciting moment for both parties” said Thomas Lethenborg, CEO at Monsenso. “Monsenso is looking to build sustainable, long-term partnerships, with the ultimate goal of delivering better care, to more people, and at lower cost.”

As part of the on-going collaboration between Monsenso and the Black Dog Institute, Mads Frost, Chief Product Officer of Monsenso, has been invited to participate as a guest-speaker at the conference “Humans and Machines: A Quest for Better Mental Health” organised by Black Dog.

Helen Christensen, Director of the Black Dog Institute, said the trial would allow them to collect real-time information using a device that most people carry at all times – their Smartphone. “Our focus will be on collecting self-reported daily mood ratings and activity data that may be used to predict changes in mental health conditions over time. Ultimately these sorts of tools can be used to deliver real time assistance to those in distress at the time they most need help. However, like all good research and development projects, our aim is to test the validity of these approaches; their feasibility and the extent that they can provide better health care services.  Ultimately, we hope to use these sorts of tools in our national programmes involving youth mental health and suicide prevention.”

The Monsenso mHealth solution for mental illnesses holds a CE mark and a TGA certification and it has been technically and clinically validated in clinical evaluation studies and randomised clinical trials. Furthermore, Monsenso is in the process of obtaining the ISO 13485 and ISO 27001.

For additional information contact:
Jennifer Highland
Marketing and Communications Manager
Monsenso
+45 81 71 7713
highland@monsenso.com

Gayle McNaught
Head of Public Affairs
The Black Dog Institute
g.mcnaught@blackdog.org.au

About The Black Dog Institute
The Black Dog Institute is a not-for-profit organisation which is internationally recognised as a pioneer in the identification, prevention and treatment of mental illnesses, and the promotion of well-being. We are dedicated to improving the lives of people affected by mental illness through the rapid translation of high quality research into improved clinical treatments, increased accessibility to mental health services and delivery of long-term public health solutions. Our unique approach incorporates clinical services with our cutting-edge research, our health professional training and community education programs. We combine expertise in clinical management with innovative research to develop new, and more effective, strategies for people living with mental disorders. For more information visit www.blackdoginstitute.org.au

 

You can download this article as PDF in English and Danish

MHealth solution receives CE Mark

MHealth solution receives CE Mark

Copenhagen, Denmark – 16 February 2016.  Monsenso ApS, a technology leader in mobile health solutions for mental health, today announced that last Friday, its mHealth solution received a CE Mark. The double-loop treatment platform that supports the treatment of major psychiatric disorders received a Class 1 Medical Device Certification under the EU Medical Devices Directive.

The certification has been obtained due to the support received from the Market Development Fund (MMF) in May 2015, which granted 2.9 million to DKK for Monsenso and its partners to obtain the necessary certifications for the solution to be ready for an international launch.

With regards to obtaining the CE Marking Certification, Thomas Lethenborg, CEO at Monsenso, commented “Obtaining this certification is an important milestone for Monsenso since our mHealth solution is based on solid research and has already been clinically validated. Our objective with this certification is to be regarded as a medical application rather than just another app.”

A CE Marking Certification guarantees that a manufacturer’s product meets the essential requirements of all relevant European Medical Device Directives.
“Holding a CE Marking Certification and offering a high level of data security is a demand from our customers across the globe. Therefore, it is important that Monsenso can distinguish itself from all other apps with no clinical evidence or inadequate security measures” added Mr. Lethenborg.

The next step for Monsenso is to obtain the ISO 27001 Data Security Certification, the ISO 13485 Certification, and to become HIPAA and FDA compliant, which is also part of the support granted by the MMF funding.

 

For additional information contact:
Jennifer Highland
Marketing and Communications Manager
Monsenso
+45 81 71 7713
highland@monsenso.com

You can download this article as PDF in English and Danish